男科
医学
癌症研究
间充质干细胞
间质细胞
造血
祖细胞
作者
Irene Cervelló,Claudia Gil-Sanchis,Xavier Santamaria,Sergio Cabanillas,Ana Díaz,Amparo Faus,Antonio Pellicer,Carlos Simón
标识
DOI:10.1016/j.fertnstert.2015.08.032
摘要
Objective To investigate the engraftment and proliferation of superparamagnetic iron oxide nanoparticles (SPIOs)-labeled human CD133 + bone marrow-derived stem cells (BMDSCs) in an animal model of Asherman syndrome (AS). Design Prospective experimental animal study. Setting University research laboratories. Animal(s) Nonobese diabetic mice (strain code 394; NOD.CB17- Prkdc scid /NcrCrl) in which AS was induced according to a published protocol. Intervention(s) Human CD133 + BMDSCs were obtained from patients undergoing autologous cell therapy in refractory AS and endometrial atrophy, labeled with SPIOs and injected either intrauterinely (n = 5) or systemically through the tail vein (n = 5) in the animal model. Main Outcome Measure(s) Accumulation of collagen and glycosaminoglycan deposits detected by trichrome staining. Percentage and localization of engrafted human SPIOs-labeled CD133 + BMDSCs by Prussian blue staining. Cell proliferation assay using Ki67 and reverse transcriptase–polymerase chain reaction (PCR) for specific paracrine factors. Result(s) The induction of the AS in the murine model was demonstrated by the accumulation of collagen and glycosaminoglycan deposits in the damaged horns by trichrome staining. Human SPIOs labeled CD133 + BMDSCs homing represents 0.59% and 0.65% of total number of cells present in the horns after intrauterine or tail vein injections, respectively. Engrafted cells were localized around endometrial blood vessels, inducing proliferation in surrounding cells based on Ki67 and regulation of the paracrine factors thrombospondin 1 and insulin-like growth factor 1. Conclusion(s) The injection of human SPIOs labeled CD133 + BMDSCs in a murine model of AS confirms that these cells engraft around endometrial vessels, inducing proliferation of surrounding cells through paracrine molecules such as thrombospondin 1 and insulin-like growth factor 1. Clinical Trial Registration Number NCT02144987.
科研通智能强力驱动
Strongly Powered by AbleSci AI